Motley Fool released an article recently titled “3 COVID-19 Vaccine Stocks That Could Be the Biggest Winners in a Post-Pandemic World”.
In the article they discuss Novavax (NASDAQ: NVAX) and how it should report interim results from a U.K. late-stage study of COVID-19 vaccine candidate NVX-CoV2373 in early 2021. The biotech hasn’t begun a late-stage study of the vaccine in the U.S. yet because of delays related to manufacturing issues. But it expects to kick off this study within the next few weeks.
Based on early-stage results, expectations are high that NVX-CoV2373 will be very effective. With other leading coronavirus vaccines already reporting efficacy levels of 94% or higher, though, Novavax probably won’t have a big competitive advantage on this front.
However, the company also hopes to win approval for its flu vaccine candidate NanoFlu. Novavax thinks there’s an opportunity to join NVX-CoV2373 with NanoFlu in a combo COVID-19/flu vaccine for post-pandemic use. If COVID-19 becomes as seasonal as the flu, this combo approach could be a huge plus for Novavax since most individuals would prefer to minimize the number of shots they get.
They also mention Arcturus Therapeitics (NASDAQ: ARTC) and Vaxart (NASDAQ: VXRT), but there is one more that should have made their list.
Another potential complimentary vaccine with dual SARS-CoV-2 and influenza application that has been overlooked is Avalon GloboCare’s (NASDAQ: AVCO) internasal vaccine.
The spray vaccine has the dual advantages of ease of manufacturing and delivery. There is also a public health advantage. For rural communities and less developed countries, the ability to more easily administer a spray vaccine, as opposed to an injectable vaccine, could facilitate wider distribution.
With the potential of a ‘twindemic’ of influenza and SARS-CoV-2 during fall and winter, Avalon GloboCare (NASDAQ: AVCO) is also planning to conjugate the S-layer matrix with an antigenic signature from both SARS-CoV-2 and the influenza virus for one spray that, if proven effective, would provide protective immunity against both viruses. Novarex trades 100X higher price then Avalon and needs the vaccine to be administered twice as opposed to once.
Avalon GloboCare (NASDAQ: AVCO) is a below the radar company developing a proprietary vaccine candidate that targets the mucosal membrane leveraging a technology called S-Layer. “This coronavirus is transmitted predominantly through droplets and airborne aerosols. Providing a first-line immune protection at the oropharynx, where the virus enters the body, is likely to be important,” Jin said.
Bio-tech stocks are highly speculative picks. None of the listed companies have products on the market yet. Their fortunes hinge on successful clinical testing of their pipeline candidates. Clinical studies can (and often do) result in failure. However with a market cap of less than 100 million Avalon GloboCare (NASDAQ: AVCO) is trading at a substantial discount relative to its industry peers and may be an investment where the reward is worth the risk.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.
Avalon GloboCare is a young, $100 million market cap company that has arguably some of the brightest minds in cell-based technology. This small cap biotechnology company is working towards the goal of changing the way we fight the devastating effects of diseases that relentlessly attack our immune systems by using our own bodies against us. In the first quarter of 2020, Avalon GloboCare successfully completed a phase 1 first-in-human clinical study of AVA-001 in China for the treatment of relapsed refractory B cell acute lymphoblastic leukemia (R/R B-ALL). 90% of R/R B-ALL patients achieved complete remission with one dose and within one month of treatment, and then proceeded to a curative-intent allogeneic bone marrow transplant. With more upcoming catalysts in Q4 2020 and early 2021, it is safe to say that there is a large potential upside in AVCO’s stock that currently trades at only $1.17. The company has been well capitalized to date and has very clean cap table relative to its industry peers making it an attractive investment.
Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.